SCHEMBL4751325

SCHEMBL4751325

Cc1ccc(N=Nc2c(O)ccc3ccccc23)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.77
KMT2A Q03164 7/20 0.77
L3MBTL1 Q9Y468 6/20 0.77
MEN1 O00255 6/20 0.77
TDP1 Q9NUW8 5/20 0.77
LMNA P02545 3/20 0.77
HSP90AA1 P07900 3/20 0.77
GAA P10253 2/20 0.77
ALPL P05186 1/20 0.77
ALPI P09923 1/20 0.77
ALPG P10696 1/20 0.77
CASP3 P42574 1/20 0.77
RECQL P46063 1/20 0.77
MMP14 P50281 1/20 0.77
SENP8 Q96LD8 1/20 0.77
SENP7 Q9BQF6 1/20 0.77
SENP6 Q9GZR1 1/20 0.77
THRB P10828 4/20 0.76
MAPK1 P28482 4/20 0.72
NPC1 O15118 4/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11143645 1.00 MAPT (0.77) MAPTKMT2AL3MBTL1MEN1TDP1
SCHEMBL3705371 0.92 MAPT (0.90) MAPTKMT2AL3MBTL1MEN1TDP1
SCHEMBL3705370 0.92 MAPT (0.90) MAPTKMT2AL3MBTL1MEN1TDP1
SCHEMBL3705373 0.92 MAPT (0.90) MAPTKMT2AL3MBTL1MEN1TDP1
SCHEMBL13449901 0.90 MAPT (0.63) MAPTKMT2AL3MBTL1MEN1TDP1
SCHEMBL10294618 0.88 THRB (0.96) MAPTKMT2AL3MBTL1MEN1TDP1
SCHEMBL20138219 0.88 THRB (0.96) MAPTKMT2AL3MBTL1MEN1TDP1
SCHEMBL1942693 0.88 THRB (0.96) MAPTKMT2AL3MBTL1MEN1TDP1
SCHEMBL506289 0.88 THRB (0.96) MAPTKMT2AL3MBTL1MEN1TDP1
SCHEMBL52298 0.88 THRB (0.96) MAPTKMT2AL3MBTL1MEN1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117776963-A Synthesis method of phenol by diazotization 新疆大学 2024-03-29 CN disclosed
US-11384381-B2 Reaction accelerating agent KIKKOMAN CORPORATION (JP) 2022-07-12 US disclosed
US-20190316174-A1 REACTION ACCELERATING AGENT KIKKOMAN CORPORATION (JP) 2019-10-17 US disclosed
US-8309696-B2 AZO pigment, electrophotographic photosensitive member, process cartridge, and electrophotographic apparatus CANON KABUSHIKI KAISHA (JP) 2012-11-13 US disclosed
US-8288066-B2 Electroconductive support with a photosensitive layer of an arylamine-based compound; high sensitivity, chargeability, residual potential, light resistance MITSUBISHI CHEMICAL CORPORATION (JP) 2012-10-16 US disclosed
US-20100075239-A1 AZO PIGMENT, ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER, PROCESS CARTRIDGE, AND ELECTROPHOTOGRAPHIC APPARATUS CANON KABUSHIKI KAISHA (JP) 2010-03-25 US disclosed
WO-2008132613-A1 HYGIENE TRAINING DEVICE AND METHOD KIMBERLY-CLARK WORLDWIDE, INC. (US) 2008-11-06 WO disclosed
EP-0229191-A1 FLY-ATTRACTIVE COMPOSITION EARTH CHEMICAL CO., LTD. (JP) 1987-07-22 EP disclosed
US-4419283-A AT LEAST THREE MUTUALLY IMMISCIBLE LIQUID PHASES SCHNEIDER RONALD A 1983-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075239-A1 AZO PIGMENT, ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER, PROCESS CARTRIDGE, AND ELECTROPHOTOGRAPHIC APPARATUS CRY1, IK, APC MAPT 2989/4885KMT2A 2223/4885L3MBTL1 4811/4885
US-11384381-B2 Reaction accelerating agent MPO, AOX1, MAOA MAPT 4544/4885KMT2A 1992/4885L3MBTL1 4849/4885
US-20190316174-A1 REACTION ACCELERATING AGENT MPO, AOX1, MAOA MAPT 4544/4885KMT2A 1992/4885L3MBTL1 4849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.